Literature DB >> 18196528

Increased distributional variance of mitochondrial DNA content associated with prostate cancer cells as compared with normal prostate cells.

Takatsugu Mizumachi1, Levan Muskhelishvili, Akihiro Naito, Jun Furusawa, Chun-Yang Fan, Eric R Siegel, Fred F Kadlubar, Udaya Kumar, Masahiro Higuchi.   

Abstract

BACKGROUND: Mitochondria are key organelles for apoptosis, and mitochondrial DNA (mtDNA) content can regulate cancer progression. Increases in mtDNA mutations and deletions have been reported in cancer; however, a detailed investigation of mtDNA content in cancer cells has not yet been conducted.
METHODS: Quantitative real-time PCR and improved extraction method were established to investigate the mtDNA content in a single prostate cell.
RESULTS: The heterogeneity of mtDNA content was demonstrated between the clones of prostate cancer cell line LNCaP and individual cells in each clone. To investigate whether large distributional variance of mtDNA content is associated with cancer initiation and/or progression, we first compared PZ-HPV-7, an HPV-transformed normal prostate epithelial cell line, with CA-HPV-10, transformed from prostate cancer cells derived from the same donor. We found an enhanced distributional variance of mtDNA content in CA-HPV-10. Then, we investigated mtDNA content in individual cells in laser microdisssected cancer and adjacent normal cells from prostate cancer tissue specimens using quantitative real-time PCR method. Results showed that the mtDNA content per cell follows a higher skewed distribution in cancer cells as compared in normal cells. We also observed that mtDNA content was increased in seven of nine (78%) of prostate cancers compared to normal prostate tissue.
CONCLUSIONS: These results indicate that prostate carcinogenesis may involve dysregulation of mtDNA content. Copyright 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18196528      PMCID: PMC2268637          DOI: 10.1002/pros.20697

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  28 in total

1.  Detection of mitochondrial DNA mutations in pancreatic cancer offers a "mass"-ive advantage over detection of nuclear DNA mutations.

Authors:  J B Jones; J J Song; P M Hempen; G Parmigiani; R H Hruban; S E Kern
Journal:  Cancer Res       Date:  2001-02-15       Impact factor: 12.701

2.  Mitochondrial DNA determines androgen dependence in prostate cancer cell lines.

Authors:  M Higuchi; T Kudo; S Suzuki; T T Evans; R Sasaki; Y Wada; T Shirakawa; J R Sawyer; A Gotoh
Journal:  Oncogene       Date:  2006-03-09       Impact factor: 9.867

3.  Mitochondria-to-nucleus stress signaling induces phenotypic changes, tumor progression and cell invasion.

Authors:  G Amuthan; G Biswas; S Y Zhang; A Klein-Szanto; C Vijayasarathy; N G Avadhani
Journal:  EMBO J       Date:  2001-04-17       Impact factor: 11.598

Review 4.  Use of laser capture microdissection, cDNA microarrays, and tissue microarrays in advancing our understanding of prostate cancer.

Authors:  M A Rubin
Journal:  J Pathol       Date:  2001-09       Impact factor: 7.996

5.  Facile detection of mitochondrial DNA mutations in tumors and bodily fluids.

Authors:  M S Fliss; H Usadel; O L Caballero; L Wu; M R Buta; S M Eleff; J Jen; D Sidransky
Journal:  Science       Date:  2000-03-17       Impact factor: 47.728

Review 6.  Prevalent mutations in prostate cancer.

Authors:  Jin-Tang Dong
Journal:  J Cell Biochem       Date:  2006-02-15       Impact factor: 4.429

7.  Mitochondrial density determines the cellular sensitivity to cisplatin-induced cell death.

Authors:  Wei Qian; Manabu Nishikawa; Anwarul Md Haque; Masaki Hirose; Masayuki Mashimo; Eisuke Sato; Masayasu Inoue
Journal:  Am J Physiol Cell Physiol       Date:  2005-08-17       Impact factor: 4.249

8.  Identification of somatic and germline mitochondrial DNA sequence variants in prostate cancer patients.

Authors:  Montserrat Gómez-Zaera; Jesús Abril; Laura González; Fernando Aguiló; Enric Condom; Marga Nadal; Virginia Nunes
Journal:  Mutat Res       Date:  2006-03-20       Impact factor: 2.433

9.  Increased mitochondrial DNA induces acquired docetaxel resistance in head and neck cancer cells.

Authors:  T Mizumachi; S Suzuki; A Naito; J Carcel-Trullols; T T Evans; P M Spring; N Oridate; Y Furuta; S Fukuda; M Higuchi
Journal:  Oncogene       Date:  2007-07-16       Impact factor: 9.867

10.  Association of decreased mitochondrial DNA content with ovarian cancer progression.

Authors:  Y Wang; V W S Liu; W C Xue; A N Y Cheung; H Y S Ngan
Journal:  Br J Cancer       Date:  2006-10-03       Impact factor: 7.640

View more
  37 in total

1.  Mitochondrial DNA content in paired normal and cancerous breast tissue samples from patients with breast cancer.

Authors:  Alex Xiu-Cheng Fan; Ramin Radpour; Mahdi Montazer Haghighi; Corina Kohler; Peng Xia; Sinuhe Hahn; Wolfgang Holzgreve; Xiao Yan Zhong
Journal:  J Cancer Res Clin Oncol       Date:  2009-01-06       Impact factor: 4.553

Review 2.  Mitochondrial determinants of cancer health disparities.

Authors:  Aaheli Roy Choudhury; Keshav K Singh
Journal:  Semin Cancer Biol       Date:  2017-05-06       Impact factor: 15.707

3.  Somatic mutations throughout the entire mitochondrial genome are associated with elevated PSA levels in prostate cancer patients.

Authors:  Anita Kloss-Brandstätter; Georg Schäfer; Gertraud Erhart; Alexander Hüttenhofer; Stefan Coassin; Christof Seifarth; Monika Summerer; Jasmin Bektic; Helmut Klocker; Florian Kronenberg
Journal:  Am J Hum Genet       Date:  2010-12-10       Impact factor: 11.025

Review 4.  The awakening of an advanced malignant cancer: an insult to the mitochondrial genome.

Authors:  Cody C Cook; Masahiro Higuchi
Journal:  Biochim Biophys Acta       Date:  2011-09-02

Review 5.  Mitochondrial dysfunction and cancer metastasis.

Authors:  Emily I Chen
Journal:  J Bioenerg Biomembr       Date:  2012-12       Impact factor: 2.945

6.  Mitochondrial DNA content: its genetic heritability and association with renal cell carcinoma.

Authors:  Jinliang Xing; Meng Chen; Christopher G Wood; Jie Lin; Margaret R Spitz; Jianzhong Ma; Christopher I Amos; Peter G Shields; Neal L Benowitz; Jian Gu; Mariza de Andrade; Gary E Swan; Xifeng Wu
Journal:  J Natl Cancer Inst       Date:  2008-07-29       Impact factor: 13.506

7.  Decreased mitochondrial DNA content in blood samples of patients with stage I breast cancer.

Authors:  Peng Xia; Han-Xiang An; Cheng-Xue Dang; Ramin Radpour; Corina Kohler; Emmanouil Fokas; Rita Engenhart-Cabillic; Wolfgang Holzgreve; Xiao Yan Zhong
Journal:  BMC Cancer       Date:  2009-12-21       Impact factor: 4.430

8.  Sequence variation in the mitochondrial gene cytochrome c oxidase subunit I and prostate cancer in African American men.

Authors:  Anna M Ray; Kimberly A Zuhlke; Albert M Levin; Julie A Douglas; Kathleen A Cooney; John A Petros
Journal:  Prostate       Date:  2009-06-15       Impact factor: 4.104

9.  Progressive tumor features accompany epithelial-mesenchymal transition induced in mitochondrial DNA-depleted cells.

Authors:  Akihiro Naito; Cody C Cook; Takatsugu Mizumachi; Mian Wang; Cheng-Hui Xie; Teresa T Evans; Thomas Kelly; Masahiro Higuchi
Journal:  Cancer Sci       Date:  2008-08       Impact factor: 6.716

10.  Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors.

Authors:  Corina Kohler; Ramin Radpour; Zeinab Barekati; Reza Asadollahi; Johannes Bitzer; Edward Wight; Nicole Bürki; Claude Diesch; Wolfgang Holzgreve; Xiao Yan Zhong
Journal:  Mol Cancer       Date:  2009-11-17       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.